United Therapeutics Corporation

• UTHR Stock Price 24h change: -0.24%. From 476.86 USD to 475.73 USD.
• UTHR closed lower on Wednesday, January 14, 2026, amid a broader Nasdaq decline (-1.00%). Despite recent completion of Phase 3 trials for Ralinepag, the stock faced mild selling pressure, continuing a consolidation phase after its December peak.
• From a technical perspective, the stock is in a "neutral-to-bearish consolidation": UTHR is trading below its 20-day ($496) and 50-day ($490) EMAs, but remains significantly above its 200-day SMA ($369). The RSI at 38.1 suggests a bearish tilt nearing oversold territory, with immediate support at $470 and resistance near $485.
• United Therapeutics recently announced that its Phase 3 ADVANCE OUTCOMES trial for Ralinepag reached completion, a significant milestone for its pulmonary arterial hypertension (PAH) pipeline.
• Notable insider activity was recorded in early January, with directors and executives selling shares between $480 and $510, contributing to recent price stagnation.
• At the J.P. Morgan Healthcare Conference (JPM26), Legend Biotech announced it expects to reach full-year profitability in 2026, driven by its CAR-T therapy Carvykti.
• Boston Scientific announced a major $14.5 billion acquisition of Penumbra on January 15, signaling a potential surge in medtech and biotech M&A activity for early 2026.

• UTHR Stock Price 24h change: -1.13%. From 482.39 USD to 476.94 USD.
The price dropped amid a broader consolidation phase in the biotech sector, following a strong performance in late 2025 and mixed sentiment from analysts regarding short-term growth prospects.
• Key Technical Indicators: RSI (14) at 48.63 (Neutral), MACD at -2.63 (Sell), and trading below its 20-day SMA but above its 50-day and 200-day SMAs. The technical profile suggests a "bullish long-term trend in a short-term pullback," as the stock consolidates after hitting recent highs.
• UBS raised its price target for United Therapeutics to $645 from $600, maintaining a "Buy" rating based on the company's strong commercial position in pulmonary arterial hypertension.
• Bank of America Securities initiated coverage or updated its view on UTHR with a "Hold" rating, citing balanced risk-reward at current valuation levels.
• United Therapeutics continues to gain attention for its organ transplantation-related technologies, with recent updates on its xenotransplantation research pipeline showing progress toward clinical milestones.
• The 2026 Biotech Showcase and J.P. Morgan Healthcare Conference (Jan 12-14) dominated sector news, with thousands of industry leaders discussing 2026 outlooks focused on M&A stability and FDA regulatory predictability.
• Analysts at RBC Capital and Leerink Partners warned that "less-than-perfect" clinical results could deflate current high valuations across the biotech sector as investors demand more "de-risked" assets in 2026.